Skip to main content
Figure 2 | Kinetoplastid Biology and Disease

Figure 2

From: Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13–15 June, 2006

Figure 2

Schematic representation of decision matrix for long-term objectives (7–10 years). Two parallel activities similar to those in short-term objectives is envisaged. New potential drug identified through synthesis/screening against L. donovani will be tested against isolates of Leishmania causing CL in a mouse model. Active compounds will be identified for further development and eventually tested in combined immuno-chemotherapy trials. New immuno-modulators will be tested in the B6 mouse model; however, the CpG's with human-specific motifs being developed for cancer therapy will be adopted for CL treatment.

Back to article page

Kinetoplastid Biology and Disease

ISSN: 1475-9292